US 12,070,496 B2
Compositions, methods and kits for eliciting an immune response
John H. Sampson, Durham, NC (US); and Duane A. Mitchell, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on May 31, 2022, as Appl. No. 17/828,554.
Application 14/681,534 is a division of application No. 13/748,096, filed on Jan. 23, 2013, granted, now 9,011,835, issued on Apr. 21, 2015.
Application 13/748,096 is a division of application No. 12/488,176, filed on Jun. 19, 2009, granted, now 8,425,898, issued on Apr. 23, 2013.
Application 17/828,554 is a continuation of application No. 16/937,801, filed on Jul. 24, 2020, granted, now 11,376,322.
Application 16/937,801 is a continuation of application No. 16/822,354, filed on Mar. 18, 2020, granted, now 11,389,530.
Application 16/822,354 is a continuation of application No. 15/676,330, filed on Aug. 14, 2017, granted, now 10,632,190, issued on Apr. 28, 2020.
Application 15/676,330 is a continuation of application No. 14/681,534, filed on Apr. 8, 2015, granted, now 9,764,026, issued on Sep. 19, 2017.
Claims priority of provisional application 61/074,582, filed on Jun. 20, 2008.
Prior Publication US 2022/0378906 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); A61K 31/7105 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 31/7105 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55533 (2013.01); A61K 2039/55538 (2013.01); A61K 2039/585 (2013.01); A61K 2039/812 (2018.08); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01)] 34 Claims
 
1. A method of eliciting in a subject an immune response to a cancer cell that expresses a cytomegalovirus (CMV) antigen, the method comprising:
administering to the subject a composition comprising a dendritic cell comprising a polynucleotide encoding a phosphoprotein unique long 83 (ppUL83; a/k/a pp65) and/or glycoprotein UL55 (gpUL55; a/k/a gB), or immunogenic fragments thereof wherein the composition, when administered to the subject, elicits an immune response to the cancer cell, and wherein the subject prior to the administration has been diagnosed with a cancer associated with CMV.